Physician profile
Jeffrey Y Ryu
NPI 1427039932
$8,626.32
in general payments reported to CMS, 2019-2025
33 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $360 · 2021: $1,160 · 2022: $1,655 · 2023: $1,369 · 2024: $1,631 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,571.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,365.43 | 2019-2025 | Lokelma, Farxiga, Ultomiris |
| Amgen INC. | $1,001.42 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Glaxosmithkline, LLC. | $633.70 | 2021-2025 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $618.93 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $616.79 | 2022-2025 | Filspari |
| Calliditas Therapeutics US INC. | $545.84 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $527.81 | 2021-2025 | Veltassa, Korsuva |
| Opko Pharmaceuticals, LLC | $477.68 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $407.99 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $377.41 | 2022-2025 | Terlivaz, Acthar |
| Aurinia Pharma U.S., INC. | $314.89 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $287.30 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Horizon Therapeutics Plc | $274.41 | 2019-2023 | Krystexxa |
| Daiichi Sankyo INC. | $252.33 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $208.58 | 2019-2025 | Velphoro, Velphoro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $146.81 | 2019-2023 | Nxstage System One |
| Alexion Pharmaceuticals, INC. | $100.18 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $95.42 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $72.78 | 2019-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.11 | 2023-2024 | Jardiance |
| Pacira Pharmaceuticals Incorporated | $34.33 | 2022 | |
| Amicus Therapeutics, INC. | $34.15 | 2019-2021 | |
| Ardelyx, INC. | $26.01 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $23.41 | 2024 | Gattex |
| Ultragenyx Pharmaceutical INC. | $22.70 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.17 | 2024 | Jynarque |
| Kyowa Kirin, INC. | $20.98 | 2024 | Crysvita |
| Novartis Pharmaceuticals Corporation | $18.05 | 2025 | |
| Pharmacosmos Therapeutics INC. | $13.91 | 2021 | |
| Apellis Pharmaceuticals, INC. | $13.80 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Ryu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.